Patents Assigned to The Board of Regents of the University of Texas Systems
-
Publication number: 20250034091Abstract: Compositions for treating a neurological disorder comprise lanosterol synthase inhibitors.Type: ApplicationFiled: September 20, 2024Publication date: January 30, 2025Applicant: Board of Regents, The University of Texas SystemInventors: Jef De Brabander, Deepak Nijhawan, Huayu Wang, Christopher Carroll, Thu Nguyen
-
Patent number: 12207834Abstract: The disclosure provides a surgical apparatus comprising: a steerable member that is bendable and comprises a plurality of bending segments with channels therein; and a plurality of bending actuation wires that are arranged to pass through the steerable member and cause the steerable member to bend, the steerable member comprising at least one outwardly opening lumen through which the bending actuation wires pass.Type: GrantFiled: May 4, 2021Date of Patent: January 28, 2025Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Daniel H. Kim, Dong Suk Shin, Taeho Jang, Yong Man Park
-
Patent number: 12209240Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: GrantFiled: October 12, 2021Date of Patent: January 28, 2025Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David Greenberg, Bruce L. Geller
-
Patent number: 12201684Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.Type: GrantFiled: July 24, 2020Date of Patent: January 21, 2025Assignee: The Board of Regents, The University of Texas SystemInventors: Burton Dickey, Michael Tuvim, Scott Evans
-
Patent number: 12201700Abstract: The present invention provides targeting probe, imaging probes, and probes for use as a medicament to treat damaged cartilage, where the probe targets injured tissue and can then be imaged and/or release agents to trigger the migration of surrounding chondrocytes from healthy tissue to injured tissue and/or recruit synovial stem cells.Type: GrantFiled: October 5, 2016Date of Patent: January 21, 2025Assignees: Board of Regents, The University of Texas SystemInventors: Liping Tang, Jun Zhou, Joseph Borrelli
-
Patent number: 12202895Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.Type: GrantFiled: September 12, 2019Date of Patent: January 21, 2025Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, IMMUNE-ONC THERAPEUTICS, INC.Inventors: Zhiqiang An, Chengcheng Zhang, Ningyan Zhang, Xun Gui, Mi Deng, Tao Huang, Qiang Liu, X. Charlene Liao
-
Patent number: 12202877Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.Type: GrantFiled: April 19, 2019Date of Patent: January 21, 2025Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Cassian Yee, Ke Pan
-
Patent number: 12203138Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.Type: GrantFiled: February 23, 2021Date of Patent: January 21, 2025Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of CaliforniaInventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
-
Patent number: 12203107Abstract: A crystal structure of a Non-LTR-retroelement reverse transcriptase and methods of using the same to identify enzymes with improved activity are provided. Mutant reverse transcriptase enzymes and methods of using the same are also provided.Type: GrantFiled: May 10, 2022Date of Patent: January 21, 2025Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Jennifer L. Stamos, Alfred M. Lentzsch, Seung Kuk Park, Georg Mohr, Alan M. Lambowitz
-
Publication number: 20250019465Abstract: Provided herein are single domain antibodies (sdAbs) having a specific affinity for a rare heparan sulfate moiety which can be used to disrupt DC-HIL function to reduce and prevent cancer progression and metastasis. Compositions and methods of use thereof are also provided for use of these sdAbs to treat cancer and cancer metastasis in a subject in need thereof.Type: ApplicationFiled: November 14, 2022Publication date: January 16, 2025Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Kiyoshi ARIIZUMI, Jin-Sung CHUNG, Ponciano D. CRUZ, Jr.
-
Publication number: 20250017926Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide, eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 31, 2024Publication date: January 16, 2025Applicant: Board of Regents, The University of Texas SystemInventors: Greg Dussor, Jacob E. Lackovic
-
Patent number: 12195804Abstract: The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K/mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K/mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K/mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.Type: GrantFiled: February 13, 2020Date of Patent: January 14, 2025Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Faye Johnson, Mitchell Jay Frederick
-
Patent number: 12193786Abstract: A hyperspectral imaging system can include a first hyperspectral imaging camera that is configured to provide first hyperspectral image data of an object in a first field of view. A second hyperspectral imaging camera can be separated from the first hyperspectral imaging camera, where the second hyperspectral imaging camera is configured to provide second hyperspectral image data of the object in a second field of view. A processor circuit can be operatively coupled to the first and second hyperspectral imaging cameras, where the processor circuit configured to combine the first and second hyperspectral image data to generate a hypercube of data for the object comprising spectral data included in the first and second hyperspectral image data.Type: GrantFiled: November 2, 2023Date of Patent: January 14, 2025Assignee: Boards of Regents, The University of Texas SystemInventor: Baowei Fei
-
Patent number: 12194319Abstract: Provided herein are noninvasive stimulation methods and apparatus for the treatment of injury to tissues using a novel pulsed laser system that combines the benefits of near-infrared laser light and optoacoustic waves. In certain embodiments, short, high-energy laser light pulses generate low intensity ultrasound waves that travel deep into brain tissues to stimulate neural function and treat neurological dysfunctions. In certain embodiments, a patient interface is provided wherein optoacoustic waves are produced by a plurality of optical absorbers overlying all of a plurality of optical fibers while in other embodiments optoacoustic waves are generated both inside the tissue and outside the tissue via a plurality of optical absorbers overlying some but not all of the optical fibers thus enabling an option of varying proportions of optoacoustic waves generated inside and outside of tissue.Type: GrantFiled: June 30, 2023Date of Patent: January 14, 2025Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Rinat O. Esenaliev, Maria-Adelaide Micci, Donald S. Prough
-
Patent number: 12193821Abstract: Manufacturing a neural interface device. Forming a neural interface probe of an implantable microelectrode body. PECVD a first amorphous silicon carbide insulation layer, forming a thin film metal trace and interface pad on the first layer, the pad on a portion of the trace. PECVD a second amorphous silicon carbide insulation layer on the first layer and covering the trace and the pad. Forming an opening in the second layer to expose the pad to an ambient environment. Patterning the first and second layers to define the neural interface probe. The probe has a rectangular cuboid shape, a cross-sectional area perpendicularly transverse to a long axis length of the probe and through any perpendicularly transverse cross-section along the long axis length is less than about 50 microns. The layers are the principle material of construction of the probe.Type: GrantFiled: December 22, 2021Date of Patent: January 14, 2025Assignees: Board of Regents, The University of Texas System, Trustees of Boston UniversityInventors: Timothy James Gardner, Stuart F. Cogan
-
Patent number: 12195803Abstract: Provided herein are methods and materials for detecting and/or treating subject (e.g. a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g. a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).Type: GrantFiled: August 7, 2018Date of Patent: January 14, 2025Assignees: The Johns Hopkins University, Board of Regents, The University of Texas System, The Research Foundation for The State University of New YorkInventors: Bert Vogelstein, Kenneth W. Kinzler, Joshua Cohen, Nickolas Papadopoulos, Anne Marie Lennon, Cristian Tomasetti, Yuxuan Wang, Georges Jabboure Netto, Rachel Karchin, Christopher Douville, Samir Hanash, Simeon Springer, Arthur P. Grollman, Kathleen Dickman
-
Patent number: 12193770Abstract: An instrument cart configured to position an instrument controller at a desired location and attitude pitch with respect to an incision location of a patient includes a base, a lift member moveable with respect to the base, a first planar translation member connected to the lift member and arcuately moveable with respect thereto, a second planar translation member connected to the first planar translation member and arcuately moveable with respect thereto, a third planar translation member connected to the second planar translation member and arcuately moveable with respect thereto, an arcuate slide base connected to the third planar translation member and moveable with respect thereto and an arcuate slide coupled to the arcuate slide base, and moveable with respect thereto; and an instrument controller coupling connected to the arcuate slide member, the instrument controller connected thereto and movable with respect thereto.Type: GrantFiled: January 17, 2020Date of Patent: January 14, 2025Assignees: Board Of Regents Of The University Of Texas System, ColubrisMX, IncInventors: Daniel H. Kim, Dong Suk Shin, Taeho Jang, Yongman Park, Jeihan Lee, Kihoon Nam, Yongchul Shin
-
Patent number: 12198352Abstract: Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.Type: GrantFiled: August 14, 2023Date of Patent: January 14, 2025Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Darin T Okuda, Braeden D Newton
-
Patent number: 12194059Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.Type: GrantFiled: March 10, 2022Date of Patent: January 14, 2025Assignee: Board of Regents, The University of Texas SystemInventor: Jian Yang
-
Patent number: 12195206Abstract: An electrospray thruster with integrated propellant storage directly embedded into small satellite structural elements integrates the volume of the thruster into the volume of the rail.Type: GrantFiled: January 4, 2023Date of Patent: January 14, 2025Assignee: Board of Regents, The University of Texas SystemInventor: Amelia Diane Greig